There are approximately 17 million people in the U.S. who suffer from some form of alcohol use disorder (AUD).
Alcohol misuse and alcohol use disorders cost the United States roughly $249 billion annually in lost productivity, healthcare expenses and criminal justice costs.
We are developing OPNT002, a nasal naltrexone for AUD. Alcohol triggers the release of naturally occurring endorphins, which then bind to the opiate receptor, leading to dopamine release in the reward center. Opioid antagonists can reduce the risk of heavy drinking by blocking opioid receptors, which results in dampening of alcohol-induced dopamine release.
OPNT002 will be taken intranasally on an ‘as needed’ (targeted) basis in anticipation of drinking and/or in high risk situations to moderate alcohol intake. Taking OPNT002 in response to these situations could also help individuals increase their situational awareness of drinking, and perhaps help make drinking less habitual.
Opiant has generated encouraging Phase 1 clinical data with OPNT002, demonstrating rapid intranasal absorption. The Company has also received supportive feedback from the FDA on a proposed development plan that we plan to advance.